口腔乾燥症治療市場規模、佔有率和成長分析：按產品類型、類別、劑型、分銷管道、應用、最終用戶和地區分類－2026-2033年產業預測

2024 年全球口乾症治療市場價值 19 億美元，預計到 2033 年將從 2025 年的 19.9 億美元成長到 29.5 億美元，預測期（2026-2033 年）複合年成長率為 5.0%。

全球口乾症治療市場正在不斷發展，以應對慢性口乾症帶來的沉重臨床負擔。慢性口乾症會影響患者的生活品質、口腔健康和溝通能力。該市場涵蓋處方箋唾液腺、局部唾液替代品、黏膜黏合劑和先進的再生醫學，旨在應對老齡化和放射線治療導致的口乾症日益普遍的現狀。在癌症倖存者和老年族群的需求驅動下，藥物遞送系統和緩釋機制的創新變得癒發重要。人工智慧技術在研發中的應用正在加速標靶發現並最佳化患者選擇，從而帶來更具針對性和效率的臨床試驗。隨著支付方對差異化產品的興趣日益濃厚，各公司正積極拓展創新治療方法，以滿足患者尚未被滿足的需求。

全球口乾症治療市場的成長要素

全球口乾症治療市場的成長要素主要得益於患者和醫療服務提供者對非侵入性治療方法的需求不斷成長。隨著越來越多的人傾向於選擇避免手術、減少不適感的治療方法，專門針對口乾症的產品研發和投資也顯著增加。目前，各公司正致力於開發外用製劑、唾液替代品和黏膜給藥系統，並優先考慮易用性和依從性。這種不斷變化的市場格局不僅提高了社會接受度，也簡化了特定產品類型的監管核准流程。因此，這將改善患者的就醫途徑和整體滿意度，從而促進市場擴張。

全球口乾症治療市場面臨的限制因素

由於各地監管核准流程嚴格且不一致，全球口乾症治療市場面臨嚴峻挑戰。這些要求延長了新治療方法的研發週期，造成了市場不確定性，阻礙了產品進入市場，並增加了製造商的風險。證明創新配方和醫療設備的安全性和臨床療效需要進行大規模臨床試驗，並遵守不同的地區標準，這會進一步延遲產品上市，並分散研發資源。中小企業尤其難以應付這些複雜情況，導致創新受阻，患者可選擇的新治療方法也十分有限。

全球口乾症治療市場趨勢

全球口乾症（口腔乾燥）治療市場正經歷著向個人化治療和診斷的顯著轉變，這主要得益於對個別患者特徵的日益重視。這一趨勢加速了針對特定患者需求的治療方案和伴隨診斷的研發，從而能夠針對口乾症的具體病因和患者偏好，並制定更有效的治療方案。生物標記的識別和唾液分析技術的進步，為分層治療提供了支持，不僅能夠改善症狀緩解，還能提高患者的用藥依從性。臨床醫生和研發人員越來越關注綜合診斷評估、個人化給藥方案以及針對特定病因（例如藥物引起的口乾和自體免疫口乾）的聯合治療，最終目標是實現更好的長期管理並提高患者的整體滿意度。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢
• 價值鏈分析
• 案例研究
• 技術評估
• 客戶和採購標準分析
• 管道分析
• 疾病流行病學

全球口乾症治療市場規模：依產品類型分類

• 唾液替代品
• 唾液分泌促效劑
• 牙膏（牙膏粉/牙膏凝膠）
• 全身用藥

全球口乾症治療市場規模：依類型分類

• 非處方藥
• 處方藥

全球口乾症治療市場規模：依產品類型分類

• 噴
• 凝膠
• 漱口水/漱喉液
• 錠劑

全球口乾症治療市場規模：依分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球口乾症治療市場規模：依應用領域分類

• 修格蘭氏症候群
• 癌症治療引起的口乾症
• 藥物引起的口乾症
• 其他

全球口乾症治療市場規模：依最終用戶分類

• 醫院
• 診所
• 居家照護

全球口乾症治療市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• GlaxoSmithKline plc
• Pfizer Inc.
• Colgate-Palmolive Company
• Church & Dwight Co., Inc.
• Sun Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals PLC
• Lupin Limited
• Acacia Pharma Group plc
• Parnell Pharmaceuticals Holdings Ltd.
• Cumberland Pharmaceuticals Inc.
• 3M Company
• Johnson & Johnson
• Procter & Gamble Company
• Lion Corporation
• Sunstar Group
• Biotene
• Quest Products LLC
• Forward Science
• OraCoat XyliMelts
• Penta Manufacturing Company

結論與建議

Global Xerostomia Therapeutics Market size was valued at USD 1.9 Billion in 2024 and is poised to grow from USD 1.99 Billion in 2025 to USD 2.95 Billion by 2033, growing at a CAGR of 5.0% during the forecast period (2026-2033).

The global xerostomia therapeutics market is evolving to address the significant clinical burden of chronic dry mouth, impacting quality of life, dental health, and communication. Comprising prescription sialagogues, topical saliva substitutes, mucoadhesive formulations, and advanced regenerative therapies, the sector is responding to the rising prevalence of xerostomia induced by aging and radiation therapy. Innovations in drug delivery systems and sustained-release mechanisms are increasingly important, driven by demand from cancer survivors and older populations. The integration of AI technologies in research and development accelerates target discovery and optimizes patient selection, leading to more focused and efficient trials. With payer interest in differentiated products, companies are poised to scale innovative therapies that meet the unmet needs of affected patients.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Xerostomia Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Xerostomia Therapeutics Market Segments Analysis

Global xerostomia therapeutics market is segmented by product type, type, product form, distribution channel, application, end-user and region. Based on product type, the market is segmented into Salivary Substitutes, Salivary Stimulants, Dentifrices (toothpastes, gels) and Systemic Agents. Based on type, the market is segmented into Over-the-Counter Products and Prescription Drugs. Based on product form, the market is segmented into Sprays, Gels, Mouthwashes/Rinses and Lozenges. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on application, the market is segmented into Sjogren's Syndrome, Cancer Therapy-Induced Xerostomia, Drug-Induced Xerostomia and Others. Based on end-user, the market is segmented into Hospitals, Clinics and Homecare. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Xerostomia Therapeutics Market

The drive behind the Global Xerostomia Therapeutics market is significantly influenced by the growing demand for noninvasive treatment methods among both patients and healthcare providers. As individuals increasingly prefer therapies that steer clear of surgical procedures and reduce discomfort, there has been a notable surge in investment and development of products tailored for xerostomia. Companies are now concentrating their efforts on creating topical formulations, saliva substitutes, and mucoadhesive delivery systems that prioritize user-friendliness and compliance. This evolving landscape not only fosters wider community acceptance but also streamlines regulatory approval processes for certain product categories, thus enhancing accessibility and overall patient satisfaction while propelling market expansion.

Restraints in the Global Xerostomia Therapeutics Market

The Global Xerostomia Therapeutics market faces significant challenges due to stringent and inconsistent regulatory approval processes across different regions. These requirements lead to prolonged and unpredictable development timelines for new therapies, hindering market entry and escalating risks for manufacturers. In order to demonstrate safety and clinical efficacy for innovative formulations or devices, extensive clinical trials and compliance with varying regional standards are necessary, which can further delay product launches and shift resources away from research and development. Smaller companies, in particular, may struggle with these complexities, stifling innovation and limiting the availability of new treatments for patients.

Market Trends of the Global Xerostomia Therapeutics Market

The Global Xerostomia Therapeutics market is witnessing a significant shift towards personalized therapy and diagnostics, driven by the growing emphasis on individualized patient profiles. This trend facilitates the development of tailored therapeutics and companion diagnostics, enabling more effective treatments customized to the specific underlying causes of xerostomia and patient preferences. Enhanced biomarker identification and salivary profiling are supporting stratified treatment approaches that not only improve symptom relief but also promote patient adherence. Clinicians and developers are increasingly focusing on integrated diagnostic assessments, personalized dosing regimens, and combination therapies aimed at particular etiologies, such as medication-induced or autoimmune-related dry mouth, ultimately fostering better long-term management and overall patient satisfaction.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Case Studies
• Technology Assessment
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Xerostomia Therapeutics Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Salivary Substitutes
• Salivary Stimulants
• Dentifrices (toothpastes gels)
• Systemic Agents

Global Xerostomia Therapeutics Market Size by Type & CAGR (2026-2033)

• Market Overview
• Over-the-Counter Products
• Prescription Drugs

Global Xerostomia Therapeutics Market Size by Product Form & CAGR (2026-2033)

• Market Overview
• Sprays
• Gels
• Mouthwashes/Rinses
• Lozenges

Global Xerostomia Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Xerostomia Therapeutics Market Size by Application & CAGR (2026-2033)

• Market Overview
• Sjogren's Syndrome
• Cancer Therapy-Induced Xerostomia
• Drug-Induced Xerostomia
• Others

Global Xerostomia Therapeutics Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Homecare

Global Xerostomia Therapeutics Market Size & CAGR (2026-2033)

• North America (Product Type, Type, Product Form, Distribution Channel, Application, End-User)
  • US
  • Canada
• Europe (Product Type, Type, Product Form, Distribution Channel, Application, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Type, Product Form, Distribution Channel, Application, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Type, Product Form, Distribution Channel, Application, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Type, Product Form, Distribution Channel, Application, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Colgate-Palmolive Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Church & Dwight Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acacia Pharma Group plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Parnell Pharmaceuticals Holdings Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cumberland Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 3M Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Procter & Gamble Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lion Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sunstar Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biotene
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Products LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Forward Science
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OraCoat XyliMelts
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Penta Manufacturing Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations